NASDAQ:NXTM - NxStage Medical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $27.84 -0.16 (-0.57 %) (As of 10/23/2018 04:00 PM ET)Previous Close$28.00Today's Range$27.77 - $28.1052-Week Range$22.70 - $28.75Volume780,800 shsAverage Volume487,688 shsMarket Capitalization$1.82 billionP/E Ratio-126.55Dividend YieldN/ABeta-0.06 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts. Receive NXTM News and Ratings via Email Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NXTM Previous Symbol CUSIP67072V10 Webwww.nxstage.com Phone978-687-4700 Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio2.36 Price-To-Earnings Trailing P/E Ratio-126.55 Forward P/E Ratio-1,392.00 P/E GrowthN/A Sales & Book Value Annual Sales$393.94 million Price / Sales4.63 Cash Flow$0.2927 per share Price / Cash95.10 Book Value$3.22 per share Price / Book8.65 Profitability EPS (Most Recent Fiscal Year)($0.22) Net Income$-14,470,000.00 Net Margins-3.67% Return on Equity-7.02% Return on Assets-4.61% Miscellaneous Employees3,800 Outstanding Shares65,580,000Market Cap$1.82 billion OptionableN/A NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions What is NxStage Medical's stock symbol? NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM." How were NxStage Medical's earnings last quarter? NxStage Medical, Inc. (NASDAQ:NXTM) issued its quarterly earnings results on Tuesday, August, 7th. The medical device company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The medical device company had revenue of $106.97 million for the quarter, compared to the consensus estimate of $105.35 million. NxStage Medical had a negative return on equity of 7.02% and a negative net margin of 3.67%. View NxStage Medical's Earnings History. When is NxStage Medical's next earnings date? NxStage Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for NxStage Medical. What price target have analysts set for NXTM? 1 Wall Street analysts have issued 1-year price targets for NxStage Medical's stock. Their forecasts range from $30.00 to $30.00. On average, they anticipate NxStage Medical's stock price to reach $30.00 in the next year. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for NxStage Medical. What is the consensus analysts' recommendation for NxStage Medical? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NxStage Medical in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NxStage Medical. Who are some of NxStage Medical's key competitors? Some companies that are related to NxStage Medical include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), AxoGen (AXGN), Natus Medical (BABY), Viewray (VRAY), Electrocore (ECOR), Cutera (CUTR), Vision Sciences (CGNT), Semler Scientific (SMLR), Rockwell Medical (RMTI), BioLife Solutions (BLFS), Helius Medical Technologies (HSDT) and Fonar (FONR). Who are NxStage Medical's key executives? NxStage Medical's management team includes the folowing people: Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 55)Mr. Joseph E. Turk Jr., Pres (Age 50)Mr. Matthew W. Towse, Sr. VP, CFO & Treasurer (Age 55)Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 54)Dr. Allan J. Collins, Head of Scientific Advisory Board & Chief Medical Officer Who are NxStage Medical's major shareholders? NxStage Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.65%) and NJ State Employees Deferred Compensation Plan (0.02%). Company insiders that own NxStage Medical stock include Craig W Moore, Daniel A Giannini, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical. Which institutional investors are selling NxStage Medical stock? NXTM stock was sold by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan. View Insider Buying and Selling for NxStage Medical. Which institutional investors are buying NxStage Medical stock? NXTM stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for NxStage Medical. How do I buy shares of NxStage Medical? Shares of NXTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NxStage Medical's stock price today? One share of NXTM stock can currently be purchased for approximately $27.84. How big of a company is NxStage Medical? NxStage Medical has a market capitalization of $1.82 billion and generates $393.94 million in revenue each year. The medical device company earns $-14,470,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. NxStage Medical employs 3,800 workers across the globe. What is NxStage Medical's official website? The official website for NxStage Medical is http://www.nxstage.com. How can I contact NxStage Medical? NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected] MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 303 (Vote Outperform)Underperform Votes: 252 (Vote Underperform)Total Votes: 555MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe NXTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/23/2018 by MarketBeat.com StaffFeatured Article: Day Trading - Risk Worth the Reward?